When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?

Solano C.; Gimenez E.; Pinana J. L.; Hernandez-Boluda J. C.; Amat P.; Vinuesa V.; Navarro D.

首页> 外文期刊>Bone marrow transplantation >When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?

【24h】

When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?

机译：什么时候应该从同种异体干细胞移植受者中取出用于活性CMV感染的先发制抗病毒治疗？

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Bone marrow transplantation》 |2017年第10期|共4页
作者
Solano C.; Gimenez E.; Pinana J. L.; Hernandez-Boluda J. C.; Amat P.; Vinuesa V.; Navarro D.;
展开▼
作者单位

Hosp Clin Univ Hematol Serv Inst Res INCLIVA Valencia Spain;

Hosp Clin Univ Inst Res INCLIVA Microbiol Serv Valencia Spain;

Hosp Clin Univ Hematol Serv Inst Res INCLIVA Valencia Spain;

Hosp Clin Univ Hematol Serv Inst Res INCLIVA Valencia Spain;

Hosp Clin Univ Hematol Serv Inst Res INCLIVA Valencia Spain;

Hosp Clin Univ Inst Res INCLIVA Microbiol Serv Valencia Spain;

Hosp Clin Univ Inst Res INCLIVA Microbiol Serv Valencia Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients? [J] . Solano C., Gimenez E., Pinana J. L., Bone marrow transplantation . 2017,第10期

机译：什么时候应该从同种异体干细胞移植受者中取出用于活性CMV感染的先发制抗病毒治疗？
2. Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood [J] . Solano C., Gimenez E., Pinana J. L., Bone marrow transplantation . 2016,第5期

机译：血液中病毒加倍时间指导异基因干细胞移植受者巨细胞病毒感染的先发性抗病毒治疗
3. Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients [J] . Estela Giménez, Carlos Solano, David Navarro, Open Forum Infectious Diseases . 2016,第2期

机译：基于病毒学和免疫学联合监测的先天性抗病毒治疗策略在同种异体干细胞移植中主动巨细胞病毒感染的有效性和安全性
4. Real-Time PCR assay and antigenemia assay: optimal threshold for guiding preemptive therapy in transplant recipients [C] . T. Lazzarotto, M. Sassi, L. Gabrielli, European Congress of Virology . 2004

机译：实时PCR测定和抗原血症测定：在移植受者中引导先发制素治疗的最佳阈值
5. The burden of parainfluenza virus infection in patients with hematological malignancy and hematopoietic stem cell transplant (HSCT) recipients in the absence of active immunization and approved therapy: The role of infection control. [D] . Hanmod, Santosh S. 2009

机译：在没有积极免疫和批准治疗的情况下，血液恶性肿瘤和造血干细胞移植（HSCT）患者的副流感病毒感染负担：感染控制的作用。
6. Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients [O] . David Navarro, Paula Amat, Rafael de la Cámara, 2016

机译：基于病毒学和免疫学联合监测的先天性抗病毒治疗策略在同种异体干细胞移植受者中主动巨细胞病毒感染的有效性和安全性
7. When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients? [O] . C Solano, E Giménez, J L Piñana, 2017

机译：什么时候应该从同种异体干细胞移植受者中取出用于活性CMV感染的先发制抗病毒治疗？

When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?

著录项

相似文献

相关主题

期刊订阅